Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy
NCT ID: NCT00655252
Last Updated: 2011-08-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NO_LONGER_AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer
NCT00446368
Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
NCT01491672
Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer
NCT01152801
Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium
NCT00805129
RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)
NCT00830895
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Everolimus
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adequate bone marrow function, liver function, renal function
* Adequate birth control
Exclusion Criteria
* Topical or inhaled steroids OK)
* Active bleeding
* Uncontrolled angina, CHF, heart attack ≤ 6 months, uncontrolled diabetes
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Highlands oncology Group, PA
Springdale, Arkansas, United States
University of Colorado Health Sciences Center/Anschutz Pavillion
Aurora, Colorado, United States
Cancer Centers of Florida, P.A.
Ocoee, Florida, United States
MD Anderson Cancer Center - Orlando
Orlando, Florida, United States
Indiana University Cancer center
Indianapolis, Indiana, United States
The Cancer Institute, St. Joseph Medical Center
Towson, Maryland, United States
Henry Ford Health System
Detroit, Michigan, United States
Missouri Cancer Associates
Columbia, Missouri, United States
Heartland Hematology-Oncology Associates, Inc.
Kansas City, Missouri, United States
Washington University/Siteman Cancer Center
St Louis, Missouri, United States
Blumenthal Cancer Center/Carolinas Medical Center
Charlotte, North Carolina, United States
Gabrail Cancer Center
Canton, Ohio, United States
Cliveland Clinic Foundation
Cleveland, Ohio, United States
Cleo Craig Memorial Cancer & Research Clinic
Lawton, Oklahoma, United States
Cancer centers of the Carolinas
Greenville, South Carolina, United States
Novartis Investigative Site
Malvern, , Australia
Novartis Investigative Site
Graz, , Austria
Novartis Investigative Site
Linz, , Austria
Novartis Investigative Site
Salzburg, , Austria
Novartis Investigative Site
Vienna, , Austria
Novartis Investigative Site
Brussels, , Belgium
Moncton Hospital
Moncton, New Brunswick, Canada
QE ll Health Sciences Centre
Halifax, Nova Scotia, Canada
Royal Victoria Hospital
Barrie, Ontario, Canada
Lakeridhe Health Corp - Oshawa
Oshawa, Ontario, Canada
Sault Area Hospital - General Site
Sault Ste. Marie, Ontario, Canada
Les Urologues Associes du CHUM
Montreal, Quebec, Canada
Centre Hospitalier Universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
Saskatoon Cancer Center
Saskatoon, Saskatchewan, Canada
Novartis Investigative Site
Brno, , Czechia
Novartis Investigative Site
Prague, , Czechia
Novartis Investigative Site
Augsburg, , Germany
Novartis Investigative Site
Bautzen, , Germany
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Bremen, , Germany
Novartis Investigative Site
Chemnitz, , Germany
Novartis Investigative site
Cologne, , Germany
Novartis Investigative Site
Dresden, , Germany
Novartis Investigative Site
Erlangen, , Germany
Novartis Investigative Site
Essen, , Germany
Novartis Investigative Site
Frankfurt, , Germany
Novartis Investigative Site
Frankfurt am Main, , Germany
Novartis Investigative Site
Freiburg im Breisgau, , Germany
Novartis Investigative Site
Fulda, , Germany
Novartis Investigative Site
Goslar, , Germany
Novartis Investigative Site
Hamburg, , Germany
Novartis Investigative Site
Hanover, , Germany
Novartis Investigative Site
Jena, , Germany
Novartis Investigative Site
Leipzig, , Germany
Novartis Investigative Site
Magdeburg, , Germany
Novartis Investigative Site
Mainz, , Germany
Novartis Investigative Site
Mannheim, , Germany
Novartis Investigative Site
München, , Germany
Novartis Investigative site
Münster, , Germany
Novartis Investidative Site
Nuremberg, , Germany
Novartis Investigative Site
Offenburg, , Germany
Novartis Investigative Site
Oldenburg, , Germany
Novartis Investigative Site
Recklinghausen, , Germany
Novartis Investigative Site
Rostock, , Germany
Novartis Investigative Site
Tübingen, , Germany
Novartis Investigative Site
Wuppertal, , Germany
Novartis Investigative Site
Budapest, , Hungary
Novartis Investigative Site
Beirut, , Lebanon
Novartis Investigative Site
Ålesund, , Norway
Novartis Investigative Site
Oslo, , Norway
Novartis Investigative Site
Geneva, , Switzerland
Novartis Investigative Site
Sankt Gallen, , Switzerland
Novartis Investigative Site
Ankara, , Turkey (Türkiye)
Novartis Investigative Site
Istanbul, , Turkey (Türkiye)
Novartis Investigative Site
Izmir, , Turkey (Türkiye)
Royal Bournemouth Hospital
Bournemouth, , United Kingdom
British Haematology and Oncology Centre
Bristol, , United Kingdom
Addenbrookes Hospital
Cambridge, , United Kingdom
CRUK
Glasgow, , United Kingdom
Southampton University Hospital NHS Trust,
Hampshire, , United Kingdom
Oncology & Haematology Clinical Tirals Unit
Leicester, , United Kingdom
Royal Free Hospital
London, , United Kingdom
Guy's and St. Thomas' NHS Foundation Trust
London, , United Kingdom
Royal Marsden Hospital
London, , United Kingdom
The Christie Hospital
Manchester, , United Kingdom
Newcastle General Hospital
Newcastle, , United Kingdom
Mount Vernon Cancer Centre
Northwood, , United Kingdom
St Luke's Wing, Royal Surrey County Hospital
Surrey, , United Kingdom
Singleton Hospital
Swansea, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bracarda S, Rottey S, Bahl A, Eichelberg C, Mellado B, Mangel L, Cattaneo A, Panneerselvam A, Grunwald V. REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis. Future Oncol. 2015;11(21):2893-903. doi: 10.2217/fon.15.241. Epub 2015 Sep 17.
Grunwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; REACT Study Group. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J Cancer. 2012 Feb;48(3):324-32. doi: 10.1016/j.ejca.2011.06.054. Epub 2011 Jul 29.
Related Links
Access external resources that provide additional context or updates about the study.
Visit NovartisClinicalTrials.com: Pre-qualify for a trial, and view a list of trials and participating study centers.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRAD001L2401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.